E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
June 28, 2017
February 3, 2025
6bec247e-a472-41b1-83c1-27ce44ad427a
Related Documents
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers : Guidance for Industry
Guidance DocumentAugust 26, 2022Center for Drug Evaluation and Research
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers: Guidance for Industry
Guidance DocumentJune 3, 2016Center for Drug Evaluation and Research
E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers
Guidance DocumentJuly 19, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox